InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,232.80
(
0.20%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.45
(
-1.30%
)
Bitcoin
70,120.23
(
-1.86%
)
Post# of 251878
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119669
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 04/05/2024 1:57:04 AM

Friday, April 05, 2024 1:57:04 AM

Post# of 251878
CTNM IPOs 7.91M* shares @$16.00:

https://www.globenewswire.com/news-release/2024/04/05/2858269/0/en/Contineum-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. …The Company has a pipeline of internally-developed programs to address multiple NI&I disorders, including PIPE-791, an LPA1 receptor antagonist, in Phase 1 clinical trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a selective inhibitor of the M1 receptor in a Phase 2 clinical trial for relapse-remitting multiple sclerosis. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson…

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up